FP-02.2

· Altimmune, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for FP-02.2, covering 2025-05-22 to 2025-05-22. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B [Phase 1]